About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy ...

Getting a diagnosis of leukemia can feel overwhelming. But multiple treatment options and support organizations can help you on your journey after diagnosis. Leukemia is a type of cancer that affects ...

Chronic lymphocytic leukemia (CLL) does not always cause symptoms in the beginning. They may not appear until the condition advances. When CLL symptoms do develop, they can include swollen lymph nodes ...